Data from 20 European countries show that in the past 15 years colorectal cancer (CRC) incidence increased among young adults. The awareness of the changing epidemiology of CRC could have a practical implication: to reconsider [more]
No more colorectal or lung cancer in phase 1 trials. Stretching the point, this could be the scenario in the near future following the trends described in an abstract presented at the International Congress on [more]
Could tailoring treatments to broad taxonomies work where targeting individual – or even multiple – genetic mutations has not? A growing number of researchers working on specific tumour types and/or across tumours believe this integrative [more]
The main common feature of cancer cells is their ability to escape to homeostatic regulation mechanisms of living. In a sense giving them immortality, causing in the absence of treatment the death of the organism, [more]
The beta-carotene fiasco warned oncologists off suggesting supplements on the basis of observational studies. But with vitamin D now in the spotlight, how should doctors respond when their patients ask if it could help? A [more]
Selected reports edited by Janet Fricker Download full article
Selected reports edited by Janet Fricker Download full article
Selected reports edited by Janet Fricker Download full article
Hopes that angiogenesis inhibition could improve outcomes when used adjuvantly in colorectal cancer received a setback at the end of April, with the announcement that the NSABP C-08 trial had failed to meet its primary [more]